Author Archives: Patricia Inacio PhD

Bellerophon, FDA Agree on Design of Phase 3 INOpulse Trial

The U.S. Food and Drug Administration (FDA) and Bellerophon Therapeutics agreed on the design of Bellerophon’s Phase 3 trial to test INOpulse — inhaled nitric oxide — in people with pulmonary fibrosis (PF) who are at risk for pulmonary hypertension (PH), the company said. INOpulse is a device that…

Top 10 Pulmonary Fibrosis Stories of 2019

Throughout 2019, Pulmonary Fibrosis News provided you daily coverage of breakthrough discoveries, promising therapies, and clinical trials related to pulmonary fibrosis (PF). As we look forward to bringing more news to patients, family members, and caregivers dealing with PF in 2020, here are the top 10 most-read articles of 2019,…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums